Ultrasound contrast developer Acusphere has posted its second-quarter results (end-June 30).
The Watertown, MA-based company recognized 25% more collaboration revenue for the quarter compared to 2007, posting $854,000 in connection with its agreement with Nycomed for European marketing rights for Imagify, and for the collaboration agreement associated with the licensing of its Hydrophobic Drug Delivery System (HDDS) to Cephalon in the first quarter of 2008. For the same period in 2007, the company posted $667,000 in revenue.
The net loss after dividends for the second quarter of 2008 was $11.6 million, a 23% decrease compared to a net loss of $15.2 million in the same period a year ago, Acusphere said.
For the six months ended June 30, Acusphere reported $1.5 million in revenue, an increase of 13% compared to $1.3 million in 2007. Net loss for the same six-month period was $24.5 million, a 9% decrease compared to $27.2 million for the period in 2007.
Related Reading
Acusphere cuts staff, July 29, 2008
Acusphere gets Nasdaq warning letter, July 15, 2008
FDA to review Acusphere's Imagify, July 1, 2008
Acusphere revenues flat for Q1 2008, May 9, 2008
Acusphere submits NDA for Imagify, April 29, 2008
Copyright © 2008 AuntMinnie.com
